In last trading session, Adma Biologics Inc (NASDAQ:ADMA) saw 3.89 million shares changing hands with its beta currently measuring 0.68. Company’s recent per share price level of $19.72 trading at $0.05 or 0.25% at ring of the bell on the day assigns it a market valuation of $4.60B. That closing price of ADMA’s stock is at a discount of -7.15% from its 52-week high price of $21.13 and is indicating a premium of 81.95% from its 52-week low price of $3.56. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.79 million shares which gives us an average trading volume of 5.29 million if we extend that period to 3-months.
For Adma Biologics Inc (ADMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adma Biologics Inc (NASDAQ:ADMA) trade information
Upright in the green during last session for gaining 0.25%, in the last five days ADMA remained trading in the green while hitting it’s week-highest on Friday, 11/01/24 when the stock touched $19.72 price level, adding 2.28% to its value on the day. Adma Biologics Inc’s shares saw a change of 336.28% in year-to-date performance and have moved 20.91% in past 5-day. Adma Biologics Inc (NASDAQ:ADMA) showed a performance of -2.98% in past 30-days. Number of shares sold short was 16.07 million shares which calculate 2.09 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 16 to the stock, which implies a fall of -23.25% to its current value. Analysts have been projecting 14 as a low price target for the stock while placing it at a high target of 18. It follows that stock’s current price would jump 29.01% in reaching the projected high whereas dropping to the targeted low would mean a gain of 29.01% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 38.68% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 471.15% while estimates for its earnings growth in next 5 years are of 20.00%.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Insiders are in possession of 2.58% of company’s total shares while institution are holding 84.81 percent of that, with stock having share float percentage of 87.06%. Investors also watch the number of corporate investors in a company very closely, which is 84.81% institutions for Adma Biologics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ADMA for having 18.64 million shares of worth $208.45 million. And as of 2024-06-30, it was holding 8.1462 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 14.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.3426 of outstanding shares, having a total worth of $162.3 million.
